
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restor... Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor. 더 보기
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.1399 | 17.2716049383 | 0.81 | 1.49 | 0.69215 | 893815 | 1.19972032 | CS |
4 | -0.2601 | -21.4958677686 | 1.21 | 1.49 | 0.69215 | 295174 | 1.17203638 | CS |
12 | -0.1501 | -13.6454545455 | 1.1 | 1.94 | 0.69215 | 221037 | 1.28954383 | CS |
26 | -0.5001 | -34.4896551724 | 1.45 | 1.94 | 0.69215 | 270600 | 1.2634312 | CS |
52 | -8.8701 | -90.3268839104 | 9.82 | 11.76 | 0.69215 | 365347 | 3.12910584 | CS |
156 | -2.9701 | -75.7678571429 | 3.92 | 11.76 | 0.69215 | 325530 | 4.70702124 | CS |
260 | -17.6601 | -94.8957549704 | 18.61 | 60.5162 | 0.69215 | 287671 | 8.85936284 | CS |
귀하가 조회한 주식이 이 박스에 나타나며 쉽게 최근 시세로 돌아갈 수 있습니다.
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관